Anthony has significant experience advising life sciences companies, private equity funds and venture capital firms on a number of merger and acquisition (M&A) and private equity transactions, including acquisitions, financing rounds, joint ventures and divestitures. He also regularly advises life sciences companies on collaborations, licensing and distribution arrangements.
Represented the shareholders of Anaconda Pharma, a French biotech, on its structured sale to the US group Biota Pharmaceuticals
Represented Arterial Remolding Technologies (ART), a French medtech developing an active bioabsorbable stent for the treatment of coronary disease, on its structured sale to the Japanese group Terumo Corporation
Advised the founders of Blink Biomedical SAS in the creation and first financing round of a new biotechnology company, formed by Valneva and the shareholders of Blink Therapeutics, and dedicated to the discovery of monoclonal antibodies
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.